1. Medtech Insight
  2. >>Business
  3. >>R&D

Angle Shares Up After New Research Released In Partnership With Illumina

Circulating Tumor Cells Analysis Found Mutations ‘Actively Spreading Cancer’

 
• By Natasha Barrow

Stock prices for liquid biopsy firm Angle Plc are up since 28 January after the release of new research. The study used Angle’s technology to detect clinically relevant mutations in circulating tumor cells that were not found in traditional circulating DNA, allowing for further insights into cancer progression, Andrew Newland, Angle CEO, told Medtech Insight.

(Shutterstock)

Research from liquid biopsy company Angle and genetic sequencing giant Illumina reveals that analyzing whole tumor cells, rather than solely DNA fragments, could provide a more comprehensive picture of cancer genetics.

“We found active, clinically relevant mutations in the intact living cells which are not present in the dead DNA fragments,”...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Geography